This announcement is a separate document:
华兴会计师事务所关于对北京康辰药业股份有限公司2023年度财务报表出具带强调事项段无保留意见审计报告的专项说明（修订版）
Special instruction on the auditor's report with emphasis of matter paragraph and unqualified opinion issued by HuaXing CPA Firm for the 2023 financial statements of Beijing Konruns Pharmaceutical Co., Ltd. (revised version).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.